BioSpace News Archive

ITM Isotope Technologies Munich SE announced that it will host a scientific symposium on precision oncology titled “Targeted Radionuclide Therapy – present and future prospects” held as an ancillary event in parallel to the 2022 ASCO® Annual Meeting.

Akari Therapeutics, Plc, a late-stage biotechnology company focused on advanced therapies for autoimmune and inflammatory diseases, announced financial results for the full year ended December 31, 2021, as well as recent pipeline progress.

Bionomics Limited announced that Dr Errol De Souza, Executive Chairman of Bionomics, will participate in three upcoming investor conferences:

PhaseBio Pharmaceuticals, Inc. announced the completion of a successful Type B pre-biologics license application meeting with the U.S. Food and Drug Administration for bentracimab, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in patients presenting with uncontrolled bleeding or in need of surgery.

Novan, Inc., announced its financial and operating results for the first quarter ended March 31, 2022 and provided a corporate update.

Chimerix announces it has entered into a definitive agreement with Emergent BioSolutions Inc. to acquire its exclusive worldwide rights to brincidofovir, including TEMBEXA®.

Emergent BioSolutions Inc. announced that it has entered into a definitive agreement with Chimerix, Inc., to acquire Chimerix’s exclusive worldwide rights to TEMBEXA®, the first antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox.

Cullinan Oncology, Inc. reported on recent and upcoming business highlights and announced its financial results for the first quarter ended March 31, 2022.

RVL Pharmaceuticals plc, a specialty pharmaceutical company, announced that Brian Markison, Chief Executive Officer, will present at two upcoming conferences as follows:

Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights.